Medindia LOGIN REGISTER
Medindia
Advertisement

Global Imaging Agents Industry

Thursday, May 19, 2011 General News
Advertisement
NEW YORK, May 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Advertisement

Global Imaging Agents Industry

http://www.reportlinker.com/p0326398/Global-Imaging-Agents-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging
Advertisement

This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following product segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

A. Contrast Media 3

X-Ray Contrast Media 3

Magnetic Resonance Imaging (MRI) Contrast Media 4

Ultrasound Contrast Media 4

B. Diagnostic Radiopharmaceuticals 4

2. INDUSTRY OVERVIEW 6

Medical Imaging Industry Under the Impact of Economic Downturn 6

Future Prospects 6

Targeted MRI Imaging - A Game Changer in the Making? 8

Developing Countries to Spur Growth 8

A Quick Primer On Imaging Agents 8

Growth Drivers 9

Growth Inhibitors 10

Changing Dynamics of Imaging Agents 11

Imaging Agents: Significant Growth Ahead 12

Rise of Non-Ionizing Imaging Techniques 12

Fusion Imaging Modalities: Greater Clinical Benefits 13

Radioactive Isotopes Utilized in PET & SPECT Imaging Procedures 13

Radiopharmaceuticals-An Exotic Tool 14

Nanomaterials Taking the Center Stage 14

Gadolinium Coated Nanoparticles- A Promising Imaging Agent 15

A Peek Into Pricing Dynamics 15

A Synoptic Overview 15

Pros & Cons 16

Positive Factors Driving Prices 16

Negative Factors Bearing Down on Prices 16

Reimbursements 17

"Under the Umbrella" 17

Europe 17

United States 17

3. MARKET TRENDS & ISSUES 19

Falling Prices Turn On the Heat 19

X-Ray Contrast Media: Declining Sector 19

MRI Contrast Media: Playing at Center Court 19

Impact Wielded by Ballooning MRI Practices 19

Ultrasound Contrast Media: A Rising Star in the Quadrant 20

Fledging Market Battles Teething Challenges 21

PET: A Prime Growth Driver for Radiopharmaceuticals 21

Nuclear Medicine: A Potential Growth Avenue for

Radiopharmaceuticals 22

Select Cardiology and Oncology Radiopharmaceuticals 22

4. COMPETITION 23

Market Structure 23

Big Guns in the Emerging MRI Market 24

Bayer Schering Pharma AG: A Pioneering Developer of MRI

Contrast Agents 24

Competitive Scenario 25

Table 1: Worldwide Imaging Agents Market (2009E): Percentage

Breakdown of Value Sales for Leading Players- GE Healthcare,

Bracco, Covidien, Bayer Schering Pharma, and Others (includes

corresponding Graph/Chart) 25

Table 2: X-ray Medical Contrast Media Market Worldwide

(2009E): Percentage Breakdown of Sales for GE Healthcare,

Bracco, Covidien, Bayer Schering Pharma and Others (includes

corresponding Graph/Chart) 25

Table 3: MRI Contrast Media Market Worldwide (2009):

Percentage Breakdown of Sales for Bayer Schering Pharma, GE

Healthcare, Bracco, Covidien and Others (includes

corresponding Graph/Chart) 26

Table 4: Radiopharmaceutical Contrast Media Market Worldwide:

Percentage Share of Leading Players for 2007 - GE Healthcare,

Bristol-Myers Squibb, Mallinckrodt/ Covidien, MDS Nordion and

Others (Revenue Share) (includes corresponding Graph/Chart) 26

5. TECHNOLOGY BREAKTHROUGHS 27

Molecular Imaging Agents: The Outer Limits 27

On Cards: Hyperpolarized Gases as Contrast Agents 27

Imaging Agents Make a Welcome Impact in the Field of

Alzheimer's Disease 28

Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging 28

A New Imaging Agent for Radiopharmaceutical Scans 28

Multi-Modal Image Registration: Combating Contrast Medium

Inconsistencies 28

Saline Flushes To Help Ensure Accurate Delivery of Contrast

Agents 29

6. PRODUCT OVERVIEW 30

Contrast Agents 30

Contrast Media: How Do They Function? 30

Where Are They Used ? 31

Evolution of Contrast Media: A Profile 31

Bismuth Nitrate: Beginning of Contrast Agents 31

Imaging Agents: Significant Developments in the Last Fifty Years 32

Schering Develops First Intravenous Contrast Agent 32

MRI: Creating a New Era for Contrast Agents 32

A Peek into the Finer Points of Differences Among Contrast Media 32

Viscosity 32

Osmolality 33

Chemotoxicity 33

Second Generation Non-Ionic Contrast Agents: An Introduction 33

Choice of the Contrast Medium: A Weighty Decision 33

Factors affecting choice of Imaging Agents 33

Taxonomy 34

Types of Contrast Media 34

X-Ray Contrast Medium 34

First Generation High Osmolar Contrast Media 35

Second Generation Low Osmolar Contrast Media or LOCM 35

Table 5: Comparative Analysis of Structure of Non-ionic and

ionic X-ray Contrast Media 35

MRI Contrast Medium 35

Role of Contrast Enhancement in MR Angiography (MRA) 37

MRI Contrast Agents for the Liver 37

Paramagnetic extracellular contrast agents 37

Hepatobiliary Gadolinium Chelates 37

Superparamagnetic Iron Oxide Particles 37

Ultrasound Contrast Medium 37

Ultrasonographic Contrast Media: What Are They? 38

Ultrasound Contrast Enhancement in Cardiology 39

Functionalities of Vascular Ultrasound Contrast Agents 39

Diagnostic Radiopharmaceuticals 39

Key Radioactive Isotopes used as Diagnostic

Radiopharmaceuticals 40

A Delineate of Diagnostic Radiopharmaceuticals 41

Diagnostic Radiopharmaceuticals: A Technical Run-Through 41

Applications 42

7. A SEGMENTAL REVIEW 43

Contrast Media 43

Popular Brands of Contrast Agents 43

X-ray Contrast Media 44

Market Scenario 44

MRI Contrast Media 45

Market Scenario 44

Ultrasound Contrast Media 45

Market Overview 45

Competitive Scenario 46

Diagnostic Radiopharmaceuticals 46

Market Overview 46

Immunoconjugates 46

Market Overview 46

Competitive Scenario 47

8. TECHNOLOGY DYNAMICS 48

Proprietary Technologies Making Significant In-Roads 48

Advanced Magnetics' Proprietary Colloidal Superparamagnetic

Particle Technology 48

Enzon's Single Chain Antigen-Binding Technology 48

Immunomedics' Antibody Technology 48

First Generation 48

Second Generation 48

Third Generation 48

NeoRx's "Painting the Target" Technology 49

Stage - I 49

Stage - II 49

Stage - III 49

Gas Encapsulation Technology for Ultrasound Contrast Media 49

Pharmacyclics' Texaphyrin Technology 50

Regulatory Bodies 50

Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA 50

Entry Barriers 50

Research Driven Markets 50

Highly Competitive Market 51

Economies of Scale 51

Substitutes in Agents Manufacturing 51

New X-ray Diagnostic Agents 51

Amide-based Macrocyclic Ligands - Potential MRI Agents 51

Gadolinium (III) Complexes - Potential MRI Contrast Agents 51

Metal-Containing Compounds Act As Potential Contrast Agents 51

Therapeutic Applications 51

Diagnostic Applications 52

Magnetic Gels as Potential MRI Contrast Agents 52

PFCs as Diagnostic Contrast Agents 52

9. PRODUCT LAUNCHES 53

GE Healthcare Receives FDA Approval for DaTscan for detecting

Dopamine Transporters 53

Targeson Launches Targestar® P-HF 53

GE Healthcare Announces Phase II Study Results of

Flutemetamol, the PET Imaging Agent for Brain Imaging 53

GE Healthcare Receives FDA Approval for Cysview, An Optical

Imaging Agent for Cystoscopic Detection of Papillary Bladder

Cancer 53

INER Develops Imaging Agents for Cerebral Blood Flow 54

Lantheus Medical Imaging Introduces Definity Ultrasound

Contrast Imaging Agent in India 54

Sanochemia Pharmazeutika Completes DCP Phase of MRT Imaging

Agent, to Introduce Within Major European Markets by 2011 54

Bayer Transfers Liver MRI Contrast Medium Resovist Injection

to I'rom Pharmaceutical 54

GE Healthcare Re-Introduces Contrast Agent, OptisonTM 54

Lantheus Medical Imaging Introduces ABLAVAR™ in Canada 55

VisEn Introduces ProSense® 750 FAST and Neutrophil ElastaseTM

680 FAST 55

Bayer Works on Development of MR Contrast Agents for Breast

Cancer Diagnosis 55

Lantheus Medical Imaging Introduces ABLAVAR™ MRA Imaging Agent 56

VisEn Introduces Cat B 680 FAST™ Imaging Agent 56

VisEn Medical Introduces GastroSense 750 Fluorescence Imaging

Agent 56

VisEn Medical Unveils VivoTag® 645 Red Fluorescent Dye 57

VisEn Medical Launches VivoTag® 680 XL Fluorescent Dye 57

AMAG Pharmaceuticals Unveils Superparamagnetic Iron Oxide

Nanopaticles 57

MabCure Unveils Monoclonal Antibodies 57

VisEn Medical Introduces ReninSense680TM FAST 58

VisEn Medical Introduces New VivoTag® 800 and OsteoSense®

Imaging Agents 58

VisEn Medical Introduces Annexin-Vivo 750 Imaging Agent 58

VisEn Introduces New Fluorescence Molecular Imaging Agent,

IntegriSense™ 750 59

Bayer to Launch Primovist™ and Nexavar™ in Japan 59

Sanochemia Unveils MR-Lux® 60

VisEn Medical Introduces New Fluorescence in Vivo Imaging

Agent, IntegriSense 60

Bayer to Unleash Radiology Management System 61

Bayer to Unveil Pre-Filled Contrast-Medium Cartridges for MRI 61

10. RECENT INDUSTRY ACTIVITY 62

University of Montana Receives Patents for Two New Brain

Imaging Agents 62

Eli Lilly Acquires Avid Radiopharmaceuticals 62

GE Global Research Secures Multi-Year NIH Grant to Develop

Nerve Imaging Agent and Imaging System 62

Agfa Healthcare Snaps Insight Agents 62

Nordion to Divest MDS Nordion S.A. 63

Sofie Biosciences Secures Funds for Research on Molecular PET

Imaging Agents 63

Aposense Signs Collaboration Agreement With Roche 63

University of Washington to Collaborate with Cardinal Health

for Advancement of Molecular Imaging 63

ImaginAb Joins Hand with GE Imanet for Developmental Drug

Research 64

Cancer Targeted Technology Inks Agreement with Bayer Pharma

for Cancer PET Imaging Agent 64

Lantheus Medical Imaging Wins Global Rights for Gadofosveset

Trisodium 64

Avid Radiopharmaceuticals Partners with Siemens PETNET

Solutions for Production of Florbetapir F 18 64

VisEn Expands Fluorescence Imaging Intellectual Patent

Portfolio through Acquisition of Bayer Schering's Portfolio 65

Cardinal Health Enters into Partnership with ProVision for

Cyclotrons 65

Center for Diagnostic Imaging Sets up New Imaging Center 65

ImaginAb Signs Sub Licensing Agreement for huJ591 with BZL

Biologics 65

Lantheus Medical Imaging and NTP Radioisotopes Sign Agreement

for Molybdenum-99 66

Lantheus Medical Imaging Purchases MS-325 Related Rights from

EPIX Pharmaceuticals 66

GE Healthcare Inks Agreement with Nycomed 66

Photocure Secures Reimbursement Approval for Hexvix in Germany 66

Agfa HealthCare to Acquire Insight Agents 67

Eckert & Ziegler Disinvests FCI Contrast Media Business 67

Guerbet Signs Distribution Agreement with Draximage for its

Nuclear Medicine Product Range 68

ImaginAb Signs Sub Licensing Agreement for huJ591 with BZL

Biologics 68

Lantheus Medical Imaging and NTP Radioisotopes Sign Agreement

for Molybdenum-99 68

Lantheus Medical Imaging Purchases MS-325 Related Rights for

Select Markets from EPIX Pharmaceuticals 69

MDS Nordion, TRIUMF and University of British Columbia Enter

into Partnership 69

Alseres Pharmaceuticals Signs Agreement for Special Protocol

Assessment of Altropane 69

Pharmalucence Wins Approval from FDA for Sestamibi Kit 70

Covidien Obtains Approval from Health Canada for Sestamibi

Injection 70

MDS Nordion Commences Production of CardioGen-82 70

Avista Capital Partners Acquires Bristol-Myers Squibb Medical

Imaging 70

Amerinet Awards Contract to Bayer HealthCare 71

Bristol-Myers Squibb Medical Imaging Changes Name to Lantheus

Medical Imaging 71

Bayer Schering Secures FDA Marketing Clearance for Primovist® 72

Bracco-Eisai Secures Approval for Iomeron® 350 and Iomeron®

350 Syringe for Use in Dynamic Liver CT 72

Covidien Signs Co-Marketing Deal with PETNET over Nuclear

Medicine Therapies 73

EPIX Receives FDA Approval for Vasovist 74

GE Global and NCI Partner to Speed-up Development of Cancer

and Heart Disease Diagnosing Nanoparticle Imaging Agents 74

Lantheus Wins Contract from PPP 75

Sanguine to Take over Rockland 75

Starpharma Holdings Enters into an Agreement with Unilever 75

GE Healthcare and Cardinal Health Enter Into a Deal 75

Jubilant to Take Over DRAXIS 76

MTTI and Bexion to Partner for Nanovesicle 76

Otsuka Takes over IPP 76

Wilex Inks Deal with IBA 77

Cytogen Corporation to Merge Business with EUSA Pharma Inc 77

Bracco Group Acquires E-Z-EM 77

EPIX Pharmaceuticals to Resubmit New Drug Application (NDA)

for Vasovist 77

Bayer Schering, FutureChem Ink Licensing Deal 78

NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive

Imaging Agent 78

11. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 79

Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals 79

Bracco Diagnostics Inks Agreement with HealthTrust Purchasing

Group 79

Bracco Diagnostics Offers MRI Products to HealthTrust

Purchasing Group 79

Bayer HealthCare Offers MRI Contrast Agent to HealthTrust 79

Bayer HealthCare Extends Contract with Premier 79

Bayer HealthCare Sets Off US Operations 79

Tyco Healthcare Renamed to Covidien Ltd 80

Covidien Offers Imaging Solutions to MedAssets Supply Chain

Systems 80

Siemens, M.D. Anderson Cancer Center Set up Research Centre 80

Bayer, Berlex Merge Operations 80

AION Diagnostics Forays Pre-Clinical Imaging Agent Market 80

ART Acquires Alerion Biomedical 80

EPIX to Merge with Predix 81

Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories 81

Bracco Diagnostics Inks Agreement with Amerinet 81

Vasovist receives Green Signal in Australia 81

AION Diagnostics Develops BioSilicon TM 81

Sonazoid Receives Import Approval 81

Schering AG Divests Radiopharmaceutical Business to Ion Beam

Applications and Institut National des Radioelements 82

Vasovist Receives European Approval 82

Albany Molecular Research Renews Supply Agreement with GE

Healthcare 82

QuantRx Biomedical Corp. Acquires Stake in FluoroPharma 82

Palatin Technologies Withdraws NeutroSpec Imaging Agent 82

Diosynth Bags Contract to Produce Imaging Agent 83

GE Healthcare Signs Marketing Agreement with PhotoCure 83

DRAXIMAGE Receives the Green Signal in Europe 83

Daiichi and Sankyo Sign a Merger Deal 83

12. PRODUCT INTRODUCTIONS IN RECENT PAST - A PERSPECTIVE BUILDER 84

Insight Agents to Launch Generic Contrast Media Solutions In

Europe 84

Researchers Develop First Biocompatible MRI Contrast Agent 84

Signalomics and Invitrogen Collaborate to Develop Nanocrystal

Reagents 84

Schering AG Collaborates with Stanford University to Develop

Molecular Imaging Agent 84

Schering and Avid to Develop Diagnostic Imaging Agents 84

US National Institutes of Health Develops two PET Imaging Agents 85

13. FOCUS ON SELECT PLAYERS 86

AMAG Pharmaceuticals, Inc. (USA) 86

Bayer Schering Pharma AG (Germany) 86

Bracco Group (Italy) 86

Covidien (USA) 87

Cytogen Corp. (USA) 87

Daiichi Sankyo Company Limited (Japan) 88

Eisai Co Ltd. (Japan) 88

GE Healthcare (UK) 88

Guerbet Group (France) 89

Lantheus Medical Imaging (USA) 89

14. GLOBAL MARKET PERSPECTIVE 90

Table 6: World Recent Past, Current & Future Analysis for

Imaging Agents by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Middle East and Latin

America Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 90

Table 7: World Historic Review for Imaging Agents by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin American Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 91

Table 8: World 11-Year Perspective for Imaging Agents by

Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Markets for Years 2005, 2010 &

2015 (includes corresponding Graph/Chart) 92

Table 9: World Recent Past, Current & Future Analysis for

Contrast Media by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Middle East and Latin

America Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 93

Table 10: World Historic Review for Contrast Media by

Geographic Region - US, Canada, Japan, Europe, Asia- Pacific

(excluding Japan), Middle East and Latin American Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 94

Table 11: World 11-Year Perspective for Contrast Media by

Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Markets for Years 2005, 2010 &

2015 (includes corresponding Graph/Chart) 95

Table 12: World Recent Past, Current & Future Analysis for

Contrast Media by Product Segments - X-Ray, MRI and Ultrasound

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 96

Table 13: World Historic Review for Contrast Media by Product

Segments - X-Ray, MRI and Ultrasound Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 97

Table 14: World 11-Year Perspective for Contrast Media by

Product Segments - Percentage Breakdown of Dollar Sales for

X-Ray, MRI and Ultrasound Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 97

Table 15: World Recent Past, Current & Future Analysis for

X-Ray Contrast Media by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Middle East and Latin

America Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 98

Table 16: World Historic Review for X-ray Contrast Media by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin American Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 99

Table 17: World 11-Year Perspective for X-Ray Contrast Media

by Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Markets for Years 2005, 2010 &

2015 (includes corresponding Graph/Chart) 100

Table 18: World Recent Past, Current & Future Analysis for MRI

Contrast Media by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Middle East and Latin

America Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 101

Table 19: World Historic Review for MRI Contrast Media by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin American Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 102

Table 20: World 11-Year Perspective for MRI Contrast Media by

Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Markets for Years 2005, 2010 &

2015 (includes corresponding Graph/Chart) 103

Table 21: World Recent Past, Current & Future Analysis for

Ultrasound Contrast Media by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Middle East and

Latin America Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 104

Table 22: World Historic Review for Ultrasound Contrast Media

by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin American Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 105

Table 23: World 11-Year Perspective for Ultrasound Contrast

Media by Geographic Region- Percentage Breakdown of Dollar

Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Middle East and Latin America Markets for Years 2005,

2010 & 2015 (includes corresponding Graph/Chart) 106

Table 24: World Recent Past, Current & Future Analysis for

Diagnostic Radiopharmaceuticals by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle

East and Latin America Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2007 through

2015 (includes corresponding Graph/Chart) 107

Table 25: World Historic Review for Diagnostic

Radiopharmaceuticals by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Middle East and Latin

American Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 108

Table 26: World 11-Year Perspective for Diagnostic

Radiopharmaceuticals by Geographic Region- Percentage

Breakdown of Dollar Sales for US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Middle East and Latin America

Markets for Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 109

15. THE UNITED STATES 110

A.Market Analysis 110

Outlook 110

Imaging Centers Feel the Heat During Recession 110

Growth Stimulants 111

Dynamics of Pricing 111

Diagnostic Radiopharmaceuticals 112

Market Scenario 112

Availability of Isotopes: A Tough Challenge 112

Radiopharmaceuticals to Drive Growth 112

Competitive Analysis - Imaging Market 113

Reimbursement Issues 113

Medicare 113

Magnetic Resonance Imaging 114

Regulatory Environment 115

Provisions Regarding Off-Label Usage of Contrast Media 116

Contrast Media 116

X-ray Contrast Media 116

MRI Contrast Media 116

Market Scenario 116

Managed Care Vs MRI Technology Diffusion 117

Ultrasound Contrast Media 117

B.Market Analytics 117

Table 27: US Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 117

Table 28: US Historic Review for Imaging Agents by Product

Segment - Contrast Media (X-ray, MRI and Ultrasound) and

Diagnostic Radiopharmaceuticals Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2006 (includes corresponding Graph/Chart) 118

Table 29: US 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 119

16. CANADA 120

A.Market Analysis 120

Outlook 120

Diagnostic Equipment Market 120

LOCM Products Approved in Canada 120

B.Market Analytics 121

Table 30: Canadian Recent Past, Current & Future Analysis

for Imaging Agents by Product Segment- Contrast Media

(X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 121

Table 31: Canadian Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 122

Table 32: Canadian 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 123

17. JAPAN 124

A.Market Analysis 124

Outlook 124

Reimbursement Issues 124

B.Market Analytics 125

Table 33: Japanese Recent Past, Current & Future Analysis

for Imaging Agents by Product Segment - Contrast Media

(X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 125

Table 34: Japanese Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 126

Table 35: Japanese 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 127

18. EUROPE 128

A.Market Analysis 128

Outlook 128

Trends 128

Reimbursement 128

Outsourcing of Imaging Diagnostics 129

Distribution Structure 129

Direct Sales 129

License Agreements 129

Distribution Agreements 130

A Price Sensitive Market 130

Macro Environment 130

Germany 130

France 130

Spain & Italy 131

Scandinavia 131

B.Market Analytics 132

Table 36: European Recent Past, Current & Future Analysis

for Imaging Agents by Geographic Region - France, Germany,

UK, Italy, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 132

Table 37: European Historic Review for Imaging Agents by

Geographic Region - France, Germany, UK, Italy, Spain,

Russia and Rest of Europe Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 133

Table 38: European 11-Year Perspective for Imaging Agents by

Geographic Region - Percentage Breakdown of Dollar Sales for

France, Germany, UK, Italy, Spain, Russia and Rest of Europe

Markets for Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 134

Table 39: European Recent Past, Current & Future Analysis

for Imaging Agents by Product Segment - Contrast Media

(X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 135

Table 40: European Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 136

Table 41: European 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 137

18a.FRANCE 138

A.Market Analysis 138

Outlook 138

Growth Stimulants 138

B.Market Analytics 138

Table 42: French Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 138

Table 43: French Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 139

Table 44: French 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) & Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 140

18b.GERMANY 141

A.Market Analysis 141

Outlook 141

B.Market Analytics 141

Table 45: German Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 141

Table 46: German Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 142

Table 47: German 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 143

18c. ITALY 144

Market Analysis 144

Table 48: Italian Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 144

Table 49: Italian Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 145

Table 50: Italian 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 146

18d.THE UNITED KINGDOM 147

A.Market Analysis 147

Outlook 147

B.Market Analytics 147

Table 51: UK Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 147

Table 52: UK Historic Review for Imaging Agents by Product

Segment - Contrast Media (X-ray, MRI and Ultrasound) and

Diagnostic Radiopharmaceuticals Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2006 (includes corresponding Graph/Chart) 148

Table 53: UK 11-Year Perspective for Imaging Agents by

Product Segment Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 149

18e. SPAIN 150

Market Analysis 150

Table 54: Spanish Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 150

Table 55: Spanish Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 151

Table 56: Spanish 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 152

18f. RUSSIA 153

Market Analysis 153

Table 57: Russian Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment -Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 153

Table 58: Russian Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 154

Table 59: Russian 11-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 155

18g. REST OF EUROPE 156

Market Analysis 156

Table 60: Rest of Europe Recent Past, Current & Future

Analysis for Imaging Agents by Product Segment - Contrast

Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 156

Table 61: Rest of Europe Historic Review for Imaging Agents

by Product Segment - Contrast Media (X-ray, MRI and

Ultrasound) and Diagnostic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 157

Table 62: Rest of Europe 11-Year Perspective for Imaging

Agents by Product Segment - Percentage Breakdown of Dollar

Sales for Contrast Media (X-ray, MRI and Ultrasound) and

Diagnostic Radiopharmaceuticals Markets for Years 2005, 2010

& 2015 (includes corresponding Graph/Chart) 158

19. ASIA-PACIFIC 159

A.Market Analysis 159

Outlook 159

MRI Market in Asia 159

ANSTO: Leading the Radiopharmaceuticals Market 159

India - A High Potential Market 159

B.Market Analytics 160

Table 63: Asia-Pacific Recent Past, Current & Future

Analysis for Imaging Agents by Product Segment - Contrast

Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 160

Table 64: Asia-Pacific Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 161

Table 65: Asia-Pacific 11-Year Perspective for Imaging

Agents by Product Segment - Percentage Breakdown of Dollar

Sales for Contrast Media (X-ray, MRI and Ultrasound) and

Diagnostic Radiopharmaceuticals Markets for Years 2005, 2010

& 2015 (includes corresponding Graph/Chart) 162

20. THE MIDDLE EAST 163

Market Analysis 163

Table 66: Middle East Recent Past, Current & Future Analysis

for Imaging Agents by Product Segment - Contrast Media

(X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 163

Table 67: Middle East Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 164

Table 68: Middle East 11-Year Perspective for Imaging Agents

by Product Segment - Percentage Breakdown of Dollar Sales

for Contrast Media (X-ray, MRI and Ultrasound) and

Diagnostic Radiopharmaceuticals Markets for Years 2005, 2010

& 2015 (includes corresponding Graph/Chart) 165

21. LATIN AMERICA 166

A.Market Analysis 166

Private Sector Boosts Healthcare Segment 166

B.Market Analytics 166

Table 69: Latin American Recent Past, Current & Future

Analysis for Imaging Agents by Product Segment - Contrast

Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 166

Table 70: Latin American Historic Review for Imaging Agents

by Product Segment - Contrast Media (X-ray, MRI and

Ultrasound) and Diagnostic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 167

Table 71: Latin American 11-Year Perspective for Imaging

Agents by Product Segment - Percentage Breakdown of Dollar

Sales for Contrast Media (X-ray, MRI and Ultrasound) and

Diagnostic Radiopharmaceuticals Markets for Years 2005, 2010

& 2015 (includes corresponding Graph/Chart) 168

COMPETITIVE LANDSCAPE

Total Companies Profiled: 55 (including Divisions/Subsidiaries - 71)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 37

Canada 3

Japan 6

Europe 19

France 2

Germany 6

The United Kingdom 3

Italy 2

Rest of Europe 6

Asia-Pacific (Excluding Japan) 5

Africa 1

------------------------------------------

To order this report:

: Global Imaging Agents Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close